Fundraising FoxLondon · Seed–Series A · 14 people tracked
Also known as 4BIO PARTNERS LLP
Find your way into 4BIO Capital
Sign up to see every warm intro you have to 4BIO Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 4BIO Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
4BIO Capital is a specialist life sciences venture capital firm concentrating on advanced therapies. The firm targets companies developing treatments that address significant unmet medical and social needs, positioning its investments to deliver both scientific innovation and social impact.
Source: firm website, verified Sep 29, 2026.
Team · 14 people
from the firm's website
Founder mafia
2 people who came through 4BIO Capital went on to found or lead other companies.
What they invest in
from 15 of 15 portfolio companiesBiotech ×13Medical Devices ×8Healthtech ×7Deep Tech ×6AI & Machine Learning ×3Consumer ×1Developer Tools ×1Impact & Social Good ×1
HQs:United States×5United Kingdom×2Switzerland×1Chile×1Germany×1Japan×1
Investments · 15 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22024 · 42023 · 22022 · 22020 · 113 dated
Hornet Therapeutics is a biotech company developing treatments for Epstein-Barr Virus (EBV) driven diseases, with a lead IDO-1 inhibitor (HTX-201) aimed at preventing EBV-implicated conditions such as post-transplantation lymphoproliferative disease.
BiotechMedical Devices
Christoph Hess(Co-founder (Professor))
March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments.
BiotechMedical DevicesHouston, US
Sarah Hein(CEO, Co-Founder)inMaksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
BoardThomas Luby(Director)inPeter Olagunju(Director)inJoseph Petrosino(Director)
Co-investorsMission BiocapitalCancer FocusCancer FundFitz Gate VenturesModi VenturesPortal Innovations+2 more
Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Darshan Dalal(Chief Medical Officer)in
Co-investorsHadean VenturesInnovestor VenturesM VenturesSofinnova PartnersBioqube Ventures
Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy.
BiotechMedical DevicesBasel, CH
Dragan Grabulovski(Co-founder and CEO)inPhilipp Spycher(Co-founder and Chief Scientific Officer)inIsabella Attinger-Toller(Co-founder)in
Co-investorsPureos BioventuresredalpineSamsung VenturesVI Partnersb2ventureKinled Holding
Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.
BiotechHealthtechMedical DevicesMunich, DE
Evis Hursever(Executive Officer)Wesley McConnell(Executive Officer)inMichael Stella(Executive Officer, Director)William Hawkins(Executive Officer)
BoardMichael Beecham(Director)Andrew Kozlov(Director)
Co-investorsCathay HealthDCVC (Data Collective)Monograph Capital PartnersDigitalis Ventures
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)Amgen VenturesHatteras Venture PartnersJDRF T1D FundNorthpond VenturesTakeda Ventures+1 more
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesPathway BioventuresSound Bioventures+1 more
Hornet is a social networking and chat app for gay men and the broader queer community, offering messaging, a content feed, short videos, and discovery features.
ConsumerImpact & Social GoodMedia & EntertainmentSocial
Christof Wittig(Founder)inDamien BrenierinMitchell Geere
Co-investors500 GlobalMoai CapitalVentech China
LUCA Science develops mitochondrial therapies that supply functional, storable mitochondria to damaged or dysfunctional cells and tissues to restore cellular energy production, targeting conditions such as ischemia-reperfusion injuries including cerebral and myocardial infarction.
BiotechDeep TechHealthtechLongevity
Co-investorsAsahi Kasei Corporate Venture CapitalFast Track InitiativeRemiges Ventures, Inc.Astellas Venture Management LLCAxil CapitalDCI Partners Co. Ltd.
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCF-Prime CapitalForesite CapitalUCL Technology FundAgent CapitalBaillie Gifford+3 more
Teambit analyzes code, meeting time, and interactions to measure and improve the performance of software development teams, delivering objective metrics.
AI & Machine LearningDeveloper ToolsSaaS
Paula Enei(Founder)in
Co-investorsGG CapitalDeerfield Management CompanyGeneral CatalystMRL Ventures FundNorwest Venture PartnersNovo Holdings
.png)
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Co-investorsACADEMY INVESTORAIN VenturesCalculus Capital Ltd.IQ CapitalLongeVCOld College Capital
.jpeg){kind=logo}
ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsCambridge Angels groupOxford Investment Opportunity Network (OION)Origin CapitalUCB Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Portfolio news
latest coverage across their companiesActithera · prnewswire.com · Jul 9, 2025
Principals & officers · per Companies House
what is this? ⓘDirector · British · since 2024
Director · British · since 2024
Director · British · since 2024
Dmitry Kuzmin — 25–50% of shares, 25–50% of voting rights, right to appoint and remove directors
Andrey Kozlov — 25–50% of shares, 25–50% of voting rights, right to appoint and remove directors
Frequently asked questions
- How many investments has 4BIO Capital made?
- 4BIO Capital has 15 tracked investments, including 6 dated in the last 24 months.
- What stage does 4BIO Capital invest at?
- 4BIO Capital invests at the Seed, Series A stages.
- What sectors does 4BIO Capital focus on?
- 4BIO Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is 4BIO Capital located?
- 4BIO Capital is headquartered in London, GB.
Images
Co-investors · 12
Takeda Ventures, Inc. is the corporate venture capital arm of Takeda, making venture-based investments in therapeutic and platform-based companies to build the pharmaceutical company's pipeline and create strategic growth opportunities.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
Pureos Bioventures is a venture capital firm that invests in private, innovative drug development companies, with a focus on next-generation biological drugs and drug formats to treat severe diseases.
Astellas Venture Management (AVM) is the wholly-owned corporate venture arm of Astellas, providing equity investments to private, early-stage biotechnology companies developing therapeutic programs and platform technologies for drug discovery.
Remiges Ventures is a venture capital firm focused on life sciences and drug discovery, backing biotech and therapeutics companies. It launched the RDiscovery Fund to incubate early-stage drug discovery projects.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
BGF is a UK and Ireland investor providing minority, patient growth capital and support to entrepreneurial small and medium-sized businesses, from early-stage deep tech and life sciences startups to established scaling companies.
82VS is a venture studio embedded within Alloy Therapeutics, a discovery platform and service provider, collaborating with academics, entrepreneurs, pharma, and VCs across company creation, drug discovery, and development.
Firms observed investing alongside 4BIO Capital, from public investor directories. Shared companies are the overlap with 4BIO Capital's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.